Standard Cosentyx Dosing Schedule
Cosentyx (secukinumab) starts with loading doses followed by maintenance. For plaque psoriasis in adults, it's 300 mg (two 150 mg subcutaneous injections) at weeks 0, 1, 2, 3, and 4, then 300 mg every 4 weeks. For psoriatic arthritis or ankylosing spondylitis, it's 150 mg (one injection) weekly for the first month, then every 4 weeks; 300 mg may be used if needed for psoriasis involvement. Dosing for other indications like hidradenitis suppurativa or non-radiographic axial spondyloarthritis follows similar patterns, often starting at 300 mg.[1][2]
When to Increase from 150 mg to 300 mg
Increase to 300 mg every 4 weeks if a patient on 150 mg shows inadequate response, particularly in psoriatic arthritis with significant psoriasis (BSA >10%). This applies after the initial loading phase. Guidelines emphasize assessing response at week 12 or later; switch only if clinical improvement is insufficient. For plaque psoriasis, prescribers may start at 300 mg for moderate-to-severe cases or body weight over 90 kg.[1][3]
No Further Increases Beyond 300 mg
Cosentyx labeling and clinical data do not support doses above 300 mg weekly or monthly. Trials like FUTURE 5 showed no added benefit from higher doses, with increased infection risk. The FDA-approved maximum is 300 mg every 4 weeks for adults.[1][2]
Factors Influencing Dosage Decisions
- Body Weight: Patients over 90 kg often require 300 mg for psoriasis to achieve PASI 75 response rates above 80%.[3]
- Response Assessment: Evaluate at 12-16 weeks using metrics like PASI score, ASDAS, or BSA. Lack of 50% improvement prompts increase or switch.
- Comorbidities: Higher doses for psoriasis-dominant psoriatic arthritis; 150 mg suffices for joint-focused cases without skin involvement.[1]
Risks of Increasing Dosage
Higher doses raise infection rates (e.g., upper respiratory infections in 14% vs. 11% on 150 mg) and candidiasis (6% vs. 3%). Monitor for IBD flares or hypersensitivity. No mortality signal in trials up to 5 years.[1][2]
Sources
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: Clinical Pharmacology Review, FUTURE Studies